January 09, 2014
1 min read

Allergan, Medytox complete licensing agreement

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Allergan has closed a license agreement with Medytox for its neurotoxin product candidates, according to a press release.

Allergan will pay Medytox an upfront cash payment of $65 million in exchange for worldwide exclusive rights, outside of Korea, to develop and commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product, the release said.

Allergan will also make additional contingent payments, including up to $116.5 million upon achieving certain development milestones, up to $180.5 million upon achieving certain commercialization milestones, as well as royalties on product sales, according to the release.